1. Home
  2. TNON vs MBAI Comparison

TNON vs MBAI Comparison

Compare TNON & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenon Medical Inc.

TNON

Tenon Medical Inc.

N/A

Current Price

$0.20

Market Cap

7.8M

Sector

Health Care

ML Signal

N/A

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

HOLD

Current Price

$1.01

Market Cap

8.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNON
MBAI
Founded
2012
2004
Country
United States
Israel
Employees
26
85
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
8.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TNON
MBAI
Price
$0.20
$1.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.4M
55.9K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$65.95
N/A
Revenue Next Year
$50.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.95
52 Week High
$2.48
$3.92

Technical Indicators

Market Signals
Indicator
TNON
MBAI
Relative Strength Index (RSI) 26.48 36.69
Support Level $0.19 N/A
Resistance Level $0.81 $1.26
Average True Range (ATR) 0.02 0.09
MACD 0.01 -0.00
Stochastic Oscillator 4.12 17.76

Price Performance

Historical Comparison
TNON
MBAI

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: